Apogee Therapeutics Inc.

05/15/2024 | Press release | Distributed by Public on 05/15/2024 14:03

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half life Extended Anti IL 13 Antibody for the Treatment of Atopic[...]